The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I)

Journal of Hypertension

Volumn 24, Issue 1, 2006, Pages 193-200

  Williams, Bryan ^a,d   Gosse, Philippe ^b   Lowe, Linda ^c   Harper, Ruth ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b HÔPITAL SAINT ANDRÉ   (France)

^c BOEHRINGER INGELHEIM LTD   (United Kingdom)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Circadian blood pressure; Ramipril; Telmisartan

Indexed keywords

RAMIPRIL; TELMISARTAN;

ACUTE SINUSITIS; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; FATIGUE; FEMALE; GRANULOMA; HEADACHE; HEMIPARESIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TINNITUS; TREATMENT OUTCOME; UMBILICAL HERNIA;

EID: 29244484441     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000194364.11516.ab     Document Type: Article

References (23)

1. Neutel JM, Smith DHG. The circadian pattern of blood pressure: cardiovascular risk and therapeutic opportunities. Curr Opin Nephrol Hypertens 1997; 6:250-256.
2. White WB. Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit 1997; 2:47-51.
3. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406.
4. Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, et al. Morning increase in onset of ischemic stroke. Stroke 1989; 20:473-476.
5. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79:733-743.
6. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11:1133-1137.
7. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5:93-98.
8. White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Impact on the early morning period. Am J Hypertens 2004; 17:347-353.
9. Kaplan NM, Sproul LE, Mulcahy WS. Large prospective study of ramipril in patients with hypertension. CARE Investigators. Clin Ther 1993; 15:810-818.
10. Sternberg H, Rosenthal T, Shamiss A, Green M. Altered circadian rhythm of blood pressure in shift workers. J Hum Hypertens 1995; 9:349-353.
11. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5:207-209.
12. Smith DH, Neutel JM, Lacourcière Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003; 21:1291-1298.
13. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003; 5:58-63.
14. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15:206-217.
15. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637-645.
16. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16(Suppl. 2):S13-S16.
17. Ball SG, Robertson JI. Clinical pharmacology of ramipril. Am J Cardiol 1987; 59:23D-27D.
18. Poirier L, de Champlain J, Larochelle P, Lamarre-Cliche M, Lacourcière Y. A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. Blood Press Monit 2004; 9:231-236.
19. Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, et al. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 1998; 11:387-396.
20. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38:E28-E32.
21. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
22. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313:1315-1322.
23. Teo K, Yusuf S, Anderson C, Mookadam F, Ramos B, Hilbrich L, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 2004; 148:52-61.